These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 28369530)

  • 1. Efficacy of Moxidectin Versus Ivermectin Against Strongyloides stercoralis Infections: A Randomized, Controlled Noninferiority Trial.
    Barda B; Sayasone S; Phongluxa K; Xayavong S; Keoduangsy K; Odermatt P; Puchkov M; Huwyler J; Hattendorf J; Keiser J
    Clin Infect Dis; 2017 Jul; 65(2):276-281. PubMed ID: 28369530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial.
    Hofmann D; Sayasone S; Sengngam K; Chongvilay B; Hattendorf J; Keiser J
    Lancet Infect Dis; 2021 Aug; 21(8):1151-1160. PubMed ID: 33798487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial.
    Sprecher VP; Hofmann D; Savathdy V; Xayavong P; Norkhankhame C; Huy R; Khieu V; Sayasone S; Hattendorf J; Keiser J
    Lancet Infect Dis; 2024 Feb; 24(2):196-205. PubMed ID: 37949090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.
    Buonfrate D; Salas-Coronas J; Muñoz J; Maruri BT; Rodari P; Castelli F; Zammarchi L; Bianchi L; Gobbi F; Cabezas-Fernández T; Requena-Mendez A; Godbole G; Silva R; Romero M; Chiodini PL; Bisoffi Z
    Lancet Infect Dis; 2019 Nov; 19(11):1181-1190. PubMed ID: 31558376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivermectin Treatment and Sanitation Effectively Reduce Strongyloides stercoralis Infection Risk in Rural Communities in Cambodia.
    Forrer A; Khieu V; Schindler C; Schär F; Marti H; Char MC; Muth S; Odermatt P
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004909. PubMed ID: 27548286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Moxidectin against
    Buchter V; Hofmann D; Häberli C; Keiser J
    ACS Infect Dis; 2021 May; 7(5):1069-1076. PubMed ID: 32991142
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children.
    Marti H; Haji HJ; Savioli L; Chwaya HM; Mgeni AF; Ameir JS; Hatz C
    Am J Trop Med Hyg; 1996 Nov; 55(5):477-81. PubMed ID: 8940976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial on ivermectin versus thiabendazole for the treatment of strongyloidiasis.
    Bisoffi Z; Buonfrate D; Angheben A; Boscolo M; Anselmi M; Marocco S; Monteiro G; Gobbo M; Bisoffi G; Gobbi F
    PLoS Negl Trop Dis; 2011 Jul; 5(7):e1254. PubMed ID: 21814588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivermectin concentration in breastmilk of a woman with Strongyloides stercoralis and human T-lymphotropic virus-I co-infection.
    Rodari P; Buonfrate D; Pomari E; Lunardi G; Bon I; Bisoffi Z; Angheben A
    Acta Trop; 2020 Feb; 202():105249. PubMed ID: 31678122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.
    Awadzi K; Opoku NO; Attah SK; Lazdins-Helds J; Kuesel AC
    PLoS Negl Trop Dis; 2014 Jun; 8(6):e2953. PubMed ID: 24968000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial.
    Opoku NO; Bakajika DK; Kanza EM; Howard H; Mambandu GL; Nyathirombo A; Nigo MM; Kasonia K; Masembe SL; Mumbere M; Kataliko K; Larbelee JP; Kpawor M; Bolay KM; Bolay F; Asare S; Attah SK; Olipoh G; Vaillant M; Halleux CM; Kuesel AC
    Lancet; 2018 Oct; 392(10154):1207-1216. PubMed ID: 29361335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxidectin: an ally to ivermectin for treating Strongyloides stercoralis?
    Bisoffi Z; Buonfrate D
    Lancet Infect Dis; 2021 Aug; 21(8):1060-1061. PubMed ID: 33798488
    [No Abstract]   [Full Text] [Related]  

  • 13. Current high prevalences of Strongyloides stercoralis and Opisthorchis viverrini infections in rural communities in northeast Thailand and associated risk factors.
    Laoraksawong P; Sanpool O; Rodpai R; Thanchomnang T; Kanarkard W; Maleewong W; Kraiklang R; Intapan PM
    BMC Public Health; 2018 Jul; 18(1):940. PubMed ID: 30064407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass Administration of Ivermectin for the Elimination of Onchocerciasis Significantly Reduced and Maintained Low the Prevalence of Strongyloides stercoralis in Esmeraldas, Ecuador.
    Anselmi M; Buonfrate D; Guevara Espinoza A; Prandi R; Marquez M; Gobbo M; Montresor A; Albonico M; Racines Orbe M; Martin Moreira J; Bisoffi Z
    PLoS Negl Trop Dis; 2015 Nov; 9(11):e0004150. PubMed ID: 26540412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albendazole and ivermectin for the control of soil-transmitted helminths in an area with high prevalence of Strongyloides stercoralis and hookworm in northwestern Argentina: A community-based pragmatic study.
    Echazú A; Juarez M; Vargas PA; Cajal SP; Cimino RO; Heredia V; Caropresi S; Paredes G; Arias LM; Abril M; Gold S; Lammie P; Krolewiecki AJ
    PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006003. PubMed ID: 28991899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ivermectin against Strongyloides stercoralis infection in jirds (Meriones unguiculatus).
    Sithithaworn P; Fujimaki Y; Mitsui Y; Prasanthong R; Yutanawiboonchai W; Aoki Y
    Exp Parasitol; 1998 Jun; 89(2):205-12. PubMed ID: 9635444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection.
    Henriquez-Camacho C; Gotuzzo E; Echevarria J; White AC; Terashima A; Samalvides F; Pérez-Molina JA; Plana MN
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD007745. PubMed ID: 26778150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in controlling strongyloidiasis.
    Satoh M; Kokaze A
    Expert Opin Pharmacother; 2004 Nov; 5(11):2293-301. PubMed ID: 15500376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases.
    Peters L; McCarthy AE; Faught C
    Int J Infect Dis; 2009 Nov; 13(6):e501-3. PubMed ID: 19501008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: strongyloidiasis refractory to treatment with ivermectin.
    Ashraf M; Gue CL; Baddour LM
    Am J Med Sci; 1996 Apr; 311(4):178-9. PubMed ID: 8602647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.